Paul de Laat

Paul de Laat

Auto-generated profile, based on publicly available information

Paul de Laat

Radboud Center for Mitochondrial Medicine (RCMM) at the Department of Pediatrics, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, PO BOX 9101, 6500 HB, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2012 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
PLPaul de Laat
Paul de Laat
SKSaskia Koene
Saskia Koene
LHLambert P. W. J. Den van Heuvel
Lambert P. W. J. Den van Heuvel
RRRichard Rodenburg
Richard Rodenburg
MJMirian C. H. Janssen
Mirian C. H. Janssen
JSJan A. M. Smeitink
Jan A. M. Smeitink
The m.3243A > G mutation has become known as the MELAS mutation. However, many other clinical phenotypes associated with this mutation have been described, most frequently being maternally inherited diabetes and deafness (MIDD). The m.3243A > G mutation, can be detected in virtually all tissues, however heteroplasmy differs between samples. Recent reports indicate, a preference to perform mutation analysis in urinary epithelial cells (UEC). To test this, and to study a correlation between the mutational load in different tissues with two mitochondrial scoring systems (NMDAS and NPMDS) we investigated 34 families carrying the m.3243A > G mutation. Heteroplasmy was determined in three non‐invasively collected samples, namely leucocytes, UEC and buccal mucosa. We included 127 patients, of which 82 carried the m.3243A > G mutation. None of the children (n = 11) had specific complaints. In adults (n = 71), a median NMDAS score of 15 (IQR 10‐24) was found. The most prevalent symptoms were hearing loss(48%), gastro‐intestinal problems(42%), exercise intolerance(38%) and glucose intolerance(37%). Ten patients had neurologic involvement. Buccal mucosa had the best correlation with the NMDAS in all adults (r = 0.437,p < 0.001), whereas UEC had the strongest correlation with the NMDAS in severely affected patients (r = 0.593,p = 0.002). Heteroplasmy declined significantly with increasing age in all three samples (leucocytes r = ‐0.705 (p < 0.001), UEC r = ‐0.374(p = 0.001), buccal mucosa r = ‐0.460(p < 0.001). In our cohort of 82 patients, the m.3243A > G mutation causes a wide variety of signs and symptoms, MIDD being far more prevalent than MELAS. Looking at the characteristics of the three non‐invasively available tissues for testing heteroplasmy we confirm that UEC are the preferred sample to test.

10 August 2010 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
PLP. de Laat
P. de Laat
MWM. L. Te Winkel
M. L. Te Winkel
ADA. S. Devos
A. S. Devos
CCC. E. Catsman-Berrevoets
C. E. Catsman-Berrevoets
RPR. Pieters
R. Pieters
Marry van den Heuvel-EibrinkMarry van den Heuvel-Eibrink
Marry van den Heuvel-Eibrink
Background: Posterior reversible encephalopathy syndrome (PRES) is characterized by seizures, headaches, altered mental status, cortical blindness and typical transient lesions on magnetic resonance imaging. Patients and methods: We describe seven childhood cancer patients with clinical and radiological symptoms of PRES, and reviewed all well-documented PRES cases reported during childhood cancer treatment. Results: Fifty-six children with PRES, including our 7 cases, were identified in the literature. Mean age at onset was 9 (range: 2–17) years. Primary diagnoses were acute lymphoblastic leukemia (n = 31), acute myeloid leukemia (n = 5), non-Hodgkin lymphoma (n = 7) and solid tumors (n = 13). PRES patients presented with seizures (n = 50), altered mental status (n = 20), visual disturbances (n = 24) and/or headaches (n = 17). PRES was associated with hypertension in 49 patients. About 86% of the patients had both clinical and radiological reversible symptoms. Four patients developed epilepsy, in one patient ataxia remained and one patient had a persistent mydriasis. Conclusion: Although PRES has predominantly been described in leukemia patients, it occurs in children with solid tumors as well. Hypertension seems to be the most important trigger for the occurrence of PRES during childhood cancer treatment. Seizures are the most common accompanying sign. Symptoms and radiological findings normalize in ∼90% of the cases, but in 10% neurological symptoms remain.

1 December 2013 in Ophthalmology
Verified
Journal Article
Closed access
PLPaul de Laat
Paul de Laat
JSJan A.M. Smeitink
Jan A.M. Smeitink
MJMirian C.H. Janssen
Mirian C.H. Janssen
JKJan E.E. Keunen
Jan E.E. Keunen
CBCamiel Boon
Camiel Boon

30 July 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MJMirian C.H. Janssen
Mirian C.H. Janssen
SKSaskia Koene
Saskia Koene
PLPaul de Laat
Paul de Laat
PHPleun Hemelaar
Pleun Hemelaar
PPPeter Pickkers
Peter Pickkers
JSJan Smeitink
Jan Smeitink
KH176 is a potent intracellular reduction–oxidation‐modulating compound developed to treat mitochondrial disease. We studied tolerability, safety, pharmacokinetics, pharmacodynamics, and efficacy of twice daily oral 100 mg KH176 for 28 days in a double‐blind, randomized, placebo‐controlled, two‐way crossover phase IIA study in 18 adult m.3243A>G patients without cardiovascular involvement. Efficacy parameters included clinical and functional outcome measures and biomarkers. The trial was registered within ClinicalTrials.gov (NCT02909400), the European Clinical Trials Database (2016‐001696‐79), and ISRCTN (43372293) (The KHENERGY study). Twice daily oral 100 mg KH176 was well tolerated and appeared safe. No serious treatment‐emergent adverse events were reported. No significant improvements in gait parameters or other outcome measures were obtained, except for a positive effect on alertness and mood, although a coincidence due to multiplicity cannot be ignored. The results of the study provide first data on safety and efficacy of KH176 in patients with mitochondrial disease and will be instrumental in designing future clinical trials.

13 May 2015
Verified
Book Chapter
Closed access
PDF file
SKSaskia Koene
Saskia Koene
PLPaul de Laat
Paul de Laat
DTDoorlène H. van Tienoven
Doorlène H. van Tienoven
GWGert Weijers
Gert Weijers
Dennis VriensDennis Vriens
Dennis Vriens
JSJan A. M. Smeitink
Jan A. M. Smeitink

8 July 2014 in Neurology
Verified
Journal Article
Closed access
PDF file
SKSaskia Koene
Saskia Koene
PLPaul de Laat
Paul de Laat
DTDoorlène H. van Tienoven
Doorlène H. van Tienoven
Dennis VriensDennis Vriens
Dennis Vriens
ABAndré M. Brandt
André M. Brandt
JSJan A.M. Smeitink
Jan A.M. Smeitink
Objectives: To determine the value of fibroblast growth factor 21 (FGF21), a recently discovered biomarker for mitochondrial disease, in predicting clinical disease severity and disease progression in adult carriers of the m.3243A>G mutation. Methods: In the context of a national inventory, the heteroplasmy levels of the m.3243A>G mutation were measured in leukocytes and urinary epithelial cells. The Newcastle Mitochondrial Disease Adult Scale score was determined and blood was drawn for measuring FGF21 concentration. Twenty-five of the included initial patients studied were then selected randomly for a follow-up study. Results: This prognostic study included 99 adult carriers of the m.3243A>G mutation. Our analysis revealed a moderate, significant correlation between FGF21 concentration and disease severity (r = 0.49; p = <0.001). No significant correlations were found between disease severity and the heteroplasmy percentage determined in urinary epithelial cells or the heteroplasmy percentage determined in leukocytes. Weak but significant correlations were also found between FGF21 concentration and the severity of the myopathy (r = 0.38; p = <0.001) and between the concentration of FGF21 and the severity of the encephalopathy (r = 0.30; p = <0.001). Repeated measurements following 25 subjects for 2 years revealed no significant correlation between FGF21 concentration and disease progression. Conclusions: Measuring FGF21 concentration had little added value in monitoring and predicting the disease course in this specific patient group.